ABCB11 p.Gly982Arg
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 12663868
[PubMed]
Trauner M et al: "Bile salt transporters: molecular characterization, function, and regulation."
No.
Sentence
Comment
631
G238V, E297G, G982R, R1153C, and R1268Q mutations prevent the protein from trafficking to the apical membrane, whereas the G238V mutant seems to be rapidly degraded by proteasomes.
X
ABCB11 p.Gly982Arg 12663868:631:14
status: NEW
No.
Sentence
Comment
160
Their bile flow rate is slightly but not significantly lower in comparison to controls, but the total bile salt output into bile is massively reduced and their liver bile salt concen- S114R G238V V284L* C336S D482G R487H S593R E636G G982R G1004D R1153CD R1268Q E186G E297G R432T I498T I498T T923P A926P R1050C R1128H S194P G260D N519S A1228V V444A K461E M677V R698H PFIC2 BRIC2 acquired cholestasis SNP Fig. 2 Putative secondary structure of Bsep (NT-005403) generated with the TOPO program (http://www.sacs.ucsf.edu/TOPO-run/wtopo.pl).
X
ABCB11 p.Gly982Arg 17051391:160:233
status: NEW
PMID: 17181454
[PubMed]
Sakurai A et al: "Prediction of drug-induced intrahepatic cholestasis: in vitro screening and QSAR analysis of drugs inhibiting the human bile salt export pump."
No.
Sentence
Comment
120
H2N COOH S56L G238V G260D C336S L339V V444A K461E D482G T923P K930X G982R R1090X R1153C Outside Inside R1268Q A1228VE1186K R1128H R1057X R1050C A926P A865V R698H E636G M677V S593R E592Q N591S R575XA570T Q558H I498T R432T R415Q R299K E297G V284A I206V S194P E186G cholestasis Expert Opin. Drug Saf. (2007) 6(1) Table 1.
X
ABCB11 p.Gly982Arg 17181454:120:68
status: NEW126 [46] - 22 2767 A→C Thr923Pro BRIC2 [45] - 22 2776 G→C Ala926Pro BRIC2 [45] - 22 2788 A→T Lys930X PFIC2 [43] - 23 2944 G→A Gly982Arg PFIC2 [47] - 23 3148 C→T Arg1050Cys BRIC2 [45] - 23 3169 C→T Arg1057X PFIC2 [35,47] - 24 3213 G→del Frame shift at position 1071 PFIC2 [47] - 24 3268 C→T Arg1090X PFIC2 [47] *Although Jansen et al. [47] reports the S114R variant, amino acid 114 in the wild type is Trp instead of Ser. BRIC2: Benign recurrent intrahepatic cholestasis type 2; del: Deletion; ICP: Intrahepatic cholestasis of pregnancy; NCBI: National Center for Biotechnology Information; PFIC2: Progressive familial intrahepatic cholestasis type 2.
X
ABCB11 p.Gly982Arg 17181454:126:150
status: NEW
PMID: 17947449
[PubMed]
Kagawa T et al: "Phenotypic differences in PFIC2 and BRIC2 correlate with protein stability of mutant Bsep and impaired taurocholate secretion in MDCK II cells."
No.
Sentence
Comment
13
The taurocholate transport activity was approximately half of the wild-type (WT) in BRIC2 mutants (A570T and R1050C), was substantially less in two PFIC2 mutants (D482G and E297G), and was almost abolished in six other PFIC2 mutants (K461E, G982R, R1153C, R1268Q, 3767-3768insC, and R1057X).
X
ABCB11 p.Gly982Arg 17947449:13:241
status: NEW19 In conclusion, taurocholate transport function was impaired in proportion to rapid degradation of Bsep protein in the mutants, which were aligned in the following order: A570T and R1050C Ͼ D482G Ͼ E297G Ͼ K461E, G982R, R1153C, R1268Q, 3767-3768insC, and R1057X.
X
ABCB11 p.Gly982Arg 17947449:19:230
status: NEW139 The positions of 8 PFIC2 mutations (E297G, K461E, D482G, G982R, R1057C, R1153C, 3767-3768insC, and R1268Q) and 2 BRIC2 mutations (A570T and R1050C) are indicated by ଝ and ଙ, respectively.
X
ABCB11 p.Gly982Arg 17947449:139:57
status: NEW165 Other PFIC2 mutants (K461E, G982R, R1153C, R1268Q, 3767-3768insC, and R1057X) did not show significant TC transport activity.
X
ABCB11 p.Gly982Arg 17947449:165:28
status: NEW184 Subcellular distribution study revealed that E297G, R1057X, A570T, and R1050C mutants were predominantly located along the apical membrane, whereas the other PFIC2 mutants (K461E, G982R, R1153C, R1268Q, and 3767-3768insC) remained intracellular (Fig. 7).
X
ABCB11 p.Gly982Arg 17947449:184:180
status: NEW188 Other PFIC2 mutant proteins (K461E, G982R, R1153C, R1268Q, and 3767-3768insC) were unstable and lost all transport activity.
X
ABCB11 p.Gly982Arg 17947449:188:36
status: NEW245 The mature form of Bsep protein (band C) of K461E, G982R, R1153C, R1268Q, and 3767-3768insC mutants was hardly detected (Fig. 6B) and, consequently, TC transport activity was abolished (Fig. 6A).
X
ABCB11 p.Gly982Arg 17947449:245:51
status: NEW290 From the view of maintenance of TC transport activity, the mutants could be aligned in the following order: A570T and R1050C Ͼ D482G Ͼ E297G Ͼ K461E, G982R, R1153C, R1268Q, 3767-3768insC, and R1057X.
X
ABCB11 p.Gly982Arg 17947449:290:168
status: NEW
No.
Sentence
Comment
188
Other common mutations include R575X, R1057X, G982R, C336S, R1153C, D482G, K461E, R1153C, R1268Q, R1090X, G238V, S114R, S593R, del 695, and del 3213 (66,67).
X
ABCB11 p.Gly982Arg 18376240:188:46
status: NEW
PMID: 18798335
[PubMed]
Wang L et al: "Degradation of the bile salt export pump at endoplasmic reticulum in progressive familial intrahepatic cholestasis type II."
No.
Sentence
Comment
4
G238V, D482G, G982R, R1153C, and R1286Q all retain Bsep to the endoplasmic reticulum (ER) to different extents.
X
ABCB11 p.Gly982Arg 18798335:4:14
status: NEW11 Furthermore, we present evidence that G982R weakly associates with various components of the ER quality control system.
X
ABCB11 p.Gly982Arg 18798335:11:38
status: NEW48 The following missense mutants were studied in this work: G238V, D482G, G982R, R1153C, and R1286Q.
X
ABCB11 p.Gly982Arg 18798335:48:72
status: NEW82 The positions of G238V, D482G, G982R, R1153C, and R1286Q are indicated by star signs in a predicted topology model of rat Bsep.
X
ABCB11 p.Gly982Arg 18798335:82:31
status: NEW95 As can be seen, there is substantial colocalization between GFP-Bsep and calnexin in mutants that are exclusively core-glycosylated or non-glycosylated, that is, G982R, R1153C, R1286Q, and ⌬Gly.
X
ABCB11 p.Gly982Arg 18798335:95:162
status: NEW99 Besides different glycosylation pattern, PFIC II mutants were also noticeably expressed at lower levels compared with the wt protein, with D482G, G982R, and ⌬Gly showing the lowest expression (Fig. 2A).
X
ABCB11 p.Gly982Arg 18798335:99:146
status: NEW119 G982R, R1286Q, and ⌬Gly were degraded over time as indicated by the decrease in the core-glycosylated form (the only form detected), whereas R1153C was relatively stable.
X
ABCB11 p.Gly982Arg 18798335:119:0
status: NEW122 In contrast, G982R and R1286Q are degraded with a half-life of approximately 1 hour (Fig. 3C).
X
ABCB11 p.Gly982Arg 18798335:122:13
status: NEW133 Because the proteasome and lysosome provide two of the major degradation mechanisms in the cell, we next examined the contribution of these two pathways to the stability of G238V, D482G, and G982R.
X
ABCB11 p.Gly982Arg 18798335:133:191
status: NEW156 In contrast, treatment with MG132 significantly stabilized the 170-kDa core-glycosylated form of G982R, D482G, and G238V.
X
ABCB11 p.Gly982Arg 18798335:156:97
status: NEW158 In contrast, the combination of ammonium chloride, leupeptin, and pepstatin only moderately increases the mature glycosylated form of D482G, while not affecting the expression of G238V or G982R.
X
ABCB11 p.Gly982Arg 18798335:158:188
status: NEW161 (A) The HEK 293 cells were transfected with the wt GFP-Bsep, G238V, D482G, and G982R.
X
ABCB11 p.Gly982Arg 18798335:161:79
status: NEW168 The HEK 293 cells were transfected with wt FLAG-Bsep (B) and G982R (C).
X
ABCB11 p.Gly982Arg 18798335:168:61
status: NEW176 The stabilization of G982R by the proteasome inhibitor was confirmed by pulse-chase studies (Fig. 5C), whereas the expression of wt Bsep is little affected by MG132 (Fig. 5B).
X
ABCB11 p.Gly982Arg 18798335:176:21
status: NEW183 However, the increase in ubiquitination is moderate for wt Bsep, compared with the mutant proteins G238V, D482G, G982R, and ⌬Gly.
X
ABCB11 p.Gly982Arg 18798335:183:113
status: NEW218 We transfected HEK cells with wt FLAG-Bsep, G982R and ⌬Gly, and isolated FLAG-Bsep by immunoprecipitation.
X
ABCB11 p.Gly982Arg 18798335:218:44
status: NEW221 Weak binding was seen between the sugar-binding ER chaperone calnexin and wt Bsep and G982R but not with the nonglycosylated ⌬Gly mutant, as expected.
X
ABCB11 p.Gly982Arg 18798335:221:86
status: NEW222 The ATPase p97, which extracts the retro-translocated proteins from the ER membrane,20 and a component of the retro-translocation complex HERP21,22 primarily associate with G982R as expected, which is a strong ERAD substrate.
X
ABCB11 p.Gly982Arg 18798335:222:173
status: NEW246 Taken together, the data from this study show that G238V, D482G, G982R, R1153C, R1286Q, and ⌬Gly mutations cause retention of Bsep in the ER to different extents.
X
ABCB11 p.Gly982Arg 18798335:246:65
status: NEW250 Mutants such as G982R and R1286Q are degraded with a half-life of approximately 1 hour.
X
ABCB11 p.Gly982Arg 18798335:250:16
status: NEW263 In addition, G238V, D482G, G982R, and ⌬Gly become relatively more ubiquitinated, compared with wt Bsep, when the function of the proteasome is inhibited, consistent with the notion that these mutant Bseps are misfolded and thus unstable.
X
ABCB11 p.Gly982Arg 18798335:263:27
status: NEW265 The ERAD substrate G982R interacts with multiple components of the ER quality control system.
X
ABCB11 p.Gly982Arg 18798335:265:19
status: NEW266 The HEK 293 cells were transfected with wt FLAG-Bsep, G982R, and ⌬Gly.
X
ABCB11 p.Gly982Arg 18798335:266:54
status: NEW291 Finally, we presented evidence that the ERAD substrates such as Bsep G982R weakly interact with components of the ER quality control system.
X
ABCB11 p.Gly982Arg 18798335:291:69
status: NEW294 For example, p97 and HERP primarily associate with G982R, which is a strong ERAD substrate (Fig. 5).
X
ABCB11 p.Gly982Arg 18798335:294:51
status: NEW295 Although calnexin interacts with both wt Bsep and G982R, the ratio of calnexin bound to Bsep is likely to be higher for G982R, because its expression level is lower than wt Bsep.
X
ABCB11 p.Gly982Arg 18798335:295:50
status: NEWX
ABCB11 p.Gly982Arg 18798335:295:120
status: NEW
PMID: 19101985
[PubMed]
Byrne JA et al: "Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing."
No.
Sentence
Comment
68
Continued Exon Nucleotide Change Predicted Protein Effect Location in Protein Associated Phenotype Prevalence or frequency* Any Defect(s) Identified Reference BRIC, 1 family (both hom) 15 c.1757CϾT T586I Adj WB BRIC 1 family (het) No splicing † 15 c.1763CϾT A588V Adj WB PFIC 2 families (both het) No protein 31, 32 15 c.1772AϾG N591S Adj WB SNP-ICP 2.6% 42 15 c.1779TϾA S593R NBF1 PFIC 1 family (het) 29 15 c.1791GϾT V597V NBF1 SNP 2.6% 42 16 c.1880TϾC I627T IC3 PFIC 1 family (het) ‡ 16 c.1964CϾT T655I IC3 BRIC / ICP / DC 1 family (het) Reduced levels of mature protein ‡ 17 c.2029AϾG M677V IC3 SNP 1.6-5.6% 39, 42-45 18 c.2093GϾA R698H IC3 SNP 0.3 - 0.8% 43, 45 18 c.2125GϾA E709K IC3 SNP-PFIC 1 family (het) ‡ 18 c.2130TϾC P710P IC3 SNP-PBC 0.5 - 3.1% 43 20-21 c.2412AϾC A804A TM8 SNP 1.1% 45 20-21 c.2453AϾT Y818F IC4 SNP-PFIC 2 families (hom) Reduced levels of mature protein ‡ 20-21 c.2494CϾT R832C IC4 PFIC 2 families (1 het, 1 consanguineous) Moderate differential splicing 31, 32 20-21 c.2576CϾG T859R IC4 PFIC 1 family (het) 31 22 c.2767AϾC T923P IC5 BRIC 1 family (het) 8 22 c.2776GϾC A926P IC5 BRIC 1 family (het) Mild exon skipping 8 23 c.2842CϾT R948C IC5 PFIC 2 families (both het) Immature protein 31 23 c.2935AϾG N979D TM11 PFIC 1 family (consanguineous) 31 23 c.2944GϾA G982R TM11 PFIC 4 families (1 hom, 1 consanguineous, 2 het) Immature protein 7, 29, 31 23 c.3011GϾA G1004D EC6 PFIC 1 family (hom) 28 24 c.3084AϾG A1028A TM12 SNP-PBC 39.86 - 56.3% Severe exon skipping 8, 43, 45 24 c.3148CϾT R1050C C term BRIC 2 familes (1 hom, 1 het) Immature protein 8 25 c.3329CϾA A1110E Adj WA PFIC 2 familes (both het) Mild exon skipping; immature protein 31 25 c.3346GϾC G1116R WA PFIC / BRIC 1 family (consanguineous) Mild exon skipping ‡ 25 c.3382CϾT R1128C NBF2 PFIC 1 family (consanguineous) Mild exon skipping; immature protein 31 25 c.3383GϾA R1128H NBF2 BRIC 1 family (hom) Mild exon skipping; greatly reduced levels of mature protein 8 26 c.3432CϾA S1144R NBF2 PFIC 1 family (het) Severe differential splicing 29 26 c.3457CϾT R1153C NBF2 PFIC 4 families (2 consanguineous, 2 het) Immature protein 7, 31, 36 26 c.3458GϾA R1153H NBF2 PFIC 4 families (2 consanguineous, 2 het) Severe differential splicing; immature protein 31 26 c.3460TϾC S1154P NBF2 PFIC 1 family (het) Severe differential splicing 31 26 c.3556GϾA E1186K NBF2 SNP 1%-10% Mild exon skipping ‡ 26 c.3589_3590 delCTinsGG L1197G NBF2 BRIC 1 family (het) † 27 c.3628AϾC T1210P Adj ABCm PFIC 1 family (hom) Immature protein 31 27 c.3631AϾG N1211D Adj ABCm SNP-PFIC 1 family (het) ‡ 27 c.3669GϾC E1223D ABCm Prolonged NNH 1 family (het) ‡ 27 c.3683CϾT A1228V Adj ABCm/WB SNP-PBC 0.8% 43 27 c.3691CϾT R1231W Adj ABCm/WB PFIC 1 family (het) Severe exon skipping; immature protein 30, 31 27 c.3692GϾA R1231Q Adj ABCm/WB PFIC 2 families (1 consanguineous, 1 het) No splicing; immature protein 31, 34 27 c.3724CϾA L1242I WB PFIC 1 family (het) 31 28 c.3892GϾA R1268Q¶ NBF2 PFIC 1 family (hom) Immature protein 7 *Prevalence or frequency is quoted depending on how data were presented in the original publication(s).
X
ABCB11 p.Gly982Arg 19101985:68:1445
status: NEW
PMID: 19642168
[PubMed]
Keitel V et al: "De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis."
No.
Sentence
Comment
29
Compared to the reference sequence NM_003742 of BSEP (ABCB11), three homozygous missense changes were found: 1331T3C (V444A),17 2453A3T (Y818F), and 2944G3A (G982R)4 (start codon numbered as "1").
X
ABCB11 p.Gly982Arg 19642168:29:158
status: NEW81 The patient`s mutations were introduced using the Quickchange-Multisite- mutagenesis kit (Stratagene) and the following primers: 2453A3T (Y818F): 5Ј-ccaatttctacagggatttgcctttgctaaatc- 3Ј; 2944G3A (G982R): 5Ј-cagaaagccaatatttacagattctgctt- tgcctttgc-3Ј.
X
ABCB11 p.Gly982Arg 19642168:81:209
status: NEW151 However, introduction of G982R alone or in combination with either V444A or Y818F (Fig. 4B) resulted in the retention of BSEPG982R, BSEPV444A/G982R, and BSEPY818F/G982R in the endoplasmic reticulum (ER) in colocalization with the ER marker protein disulfide isomerase.
X
ABCB11 p.Gly982Arg 19642168:151:25
status: NEWX
ABCB11 p.Gly982Arg 19642168:151:142
status: NEWX
ABCB11 p.Gly982Arg 19642168:151:163
status: NEW152 Combining all three mutations resulted in nondetectability of BSEPV444A/Y818F/G982R-YFP (Fig. 4C) independent of the cell type used (Supporting Fig. 3).
X
ABCB11 p.Gly982Arg 19642168:152:78
status: NEW154 Unexpectedly, K165 and K168 immunoreactivity, but no YFP fluorescence, was present in aggresomes of BSEPV444A/Y818F/ G982R-YFP-transfected cells after MG-132 treatment (Fig. 4G,J).
X
ABCB11 p.Gly982Arg 19642168:154:117
status: NEW165 Bars ϭ 10 m. BSEPV444A/Y818F/G982R-YFP within the ER-associated degradation pathway.
X
ABCB11 p.Gly982Arg 19642168:165:44
status: NEW166 Furthermore, the apparent loss of YFP fluorescence is suggestive of an incomplete expression or a major folding defect of BSEPV444A/Y818F/G982R-YFP.
X
ABCB11 p.Gly982Arg 19642168:166:138
status: NEW175 It is of note, that in addition to the G982R and Y818F mutations, the common mutation/polymorphism V444A is necessary for the complete disappearance of BSEP.
X
ABCB11 p.Gly982Arg 19642168:175:39
status: NEW176 V444A has a high prevalence in the Caucasian population,17 has been linked to the development of drug-induced liver injury,30 and may aggravate cholestatic liver diseases such as intrahepatic cholestasis of pregnan- cy31 or benign recurrent intrahepatic cholestasis.32 Expression of BSEPV444A/Y818F/G982R in hepatic and nonhepatic cell lines was below detectability.
X
ABCB11 p.Gly982Arg 19642168:176:299
status: NEW184 The presence of G982R and Y818F caused the retention of mutated BSEPY818F/G982R-YFP within the endoplasmic reticulum.
X
ABCB11 p.Gly982Arg 19642168:184:16
status: NEWX
ABCB11 p.Gly982Arg 19642168:184:74
status: NEW185 Combination of all three mutations of the patient (V444A,Y818F,G982R) induced complete absence of mutated BSEPV444A/Y818F/G982R-YFP.
X
ABCB11 p.Gly982Arg 19642168:185:63
status: NEWX
ABCB11 p.Gly982Arg 19642168:185:122
status: NEW188 (G-L) Aggresomes, induced by MG132 in BSEPV444A/Y818F/G982R-YFP-expressing cells, contained immunoreactivity for the BSEP antibodies K165 (I) and K168 (L) but no green fluorescence, suggesting incomplete expression or misfolding of BSEPV444A/Y818F/G982R-YFP.
X
ABCB11 p.Gly982Arg 19642168:188:54
status: NEWX
ABCB11 p.Gly982Arg 19642168:188:55
status: NEW
PMID: 20010382
[PubMed]
Ho RH et al: "Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability."
No.
Sentence
Comment
138
Functional analysis of bile salt export pump variants A panel of expression plasmids comprising wild-type BSEP, nine nonsynonymous BSEP variants, and two known PFIC2 BSEP missense mutants, 2944G > A (Gly982Arg) and 3457C >T (Arg1153Cys), was constructed for functional studies.
X
ABCB11 p.Gly982Arg 20010382:138:200
status: NEW
PMID: 20232290
[PubMed]
Davit-Spraul A et al: "ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history."
No.
Sentence
Comment
94
ABCB11 Mutations in PFIC2 Patients Family Mutation Allele 1 Mutation Allele 2 Biliary BA (N > 10 mmol/L) BSEP Liver Immunohistochemistry PFIC2 no. 1 p.R1090X p.R1090X 0.02 BSEP À PFIC2 no. 2 p.Y354X p.Y354X 0.02 BSEP À PFIC2 no. 3 p.Y354X p.Y354X 0.19 BSEP À PFIC2 no. 4 p.Y354X p.Y354X na na PFIC2 no.
X
ABCB11 p.Gly982Arg 20232290:94:21
status: NEW95 5a‡ p.Y354X p.G982R 0.10 BSEP À PFIC2 no.
X
ABCB11 p.Gly982Arg 20232290:95:21
status: NEW96 5b‡ p.Y354X p.G982R na na PFIC2 no.
X
ABCB11 p.Gly982Arg 20232290:96:21
status: NEW102 12† p.T1210P p.T1210P 0.11 BSEP À PFIC2 no. 13 c.3213 15 G>A p.A1192EfsX50 na BSEP À PFIC2 no.
X
ABCB11 p.Gly982Arg 20232290:102:21
status: NEW104 14b† p.I420T p.I1061VfsX34 na na PFIC2 no. 15*,‡ p.A167T p.G1058HfsX38 0.5 BSEP À PFIC2 no. 16* p.R1231W p.I528X na na PFIC2 no. 17 p.M62K p.I112T þ p.R698H 0.10 BSEP À PFIC2 no. 18* p.E297G p.H484RfsX5 0.16 BSEP À PFIC2 no. 19* p.E297G p.I610GfsX45 0.23 BSEP À PFIC2 no.
X
ABCB11 p.Gly982Arg 20232290:104:67
status: NEWX
ABCB11 p.Gly982Arg 20232290:104:175
status: NEW105 20† p.A257G p.G982R na na PFIC2 no. 21* p.I182K c.3213 15 G>A na BSEP À PFIC2 no. 22 p.D549V c.76 13 G>T na na PFIC2 no.
X
ABCB11 p.Gly982Arg 20232290:105:21
status: NEW107 24† p.R1153C c.3213 14 A>G 0.13 BSEP À PFIC2 no. 25* p.G982R p.Q101DfsX8 0.10 BSEP À PFIC2 no. 26* p.N591S þ p.V597V nf 0.39 BSEP À PFIC2 no. 27* p.G982R p.R1001R na BSEP À PFIC2 no. 28 p.L232CfsX9 nf na BSEP À PFIC2 no. 29 p.W114R nf 0.50 BSEP À PFIC2 no.
X
ABCB11 p.Gly982Arg 20232290:107:67
status: NEWX
ABCB11 p.Gly982Arg 20232290:107:175
status: NEW
PMID: 20422495
[PubMed]
Lam P et al: "The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease."
No.
Sentence
Comment
77
Ubiquitylation is involved in the degradation of receptors, channels, and transporters from the endoplasmic reticulum and cell surface of yeast and higher eukaryotes.86-88 Wang et al, showed for the first time that specific E3 ubiquitin ligases are involved in Bsep degradation.58 Bsep mutants (p.G238V, p.D482G, p.G982R, p.R1153C, and p.R1268Q) were highly ubiquitinated following overexpression of different E3 ubiquitin ligases and were rapidly degraded by proteasomes resulting in shorter half-lives compared with the wild-type protein.58 This study suggests that stabilizing aberrant BSEP proteins by inactivating key E3 ubiquitin ligases might be a novel therapeutic approach, providing that global effects on proteasomal degradation can be avoided.
X
ABCB11 p.Gly982Arg 20422495:77:315
status: NEW
PMID: 21219577
[PubMed]
Shimizu H et al: "Living-related liver transplantation for siblings with progressive familial intrahepatic cholestasis 2, with novel genetic findings."
No.
Sentence
Comment
104
The common mutations include E297G, R575X, R1057X, G982R, C336S, R1153C, D482G, K461E, R1153C, R1268Q, R1090X, G238V, S114R, S593R, del 695 and del 3213 (22).
X
ABCB11 p.Gly982Arg 21219577:104:51
status: NEW
PMID: 21490445
[PubMed]
Evason K et al: "Morphologic findings in progressive familial intrahepatic cholestasis 2 (PFIC2): correlation with genetic and immunohistochemical studies."
No.
Sentence
Comment
143
Immunohistochemical Findings and Genetic Abnormalities Patient BSEP Mutation Type of Mutation(s) 1 Absent c.890A>G (p.E297G)* Missense5,7,10,13,16,19,20 2 Absent c.1723C>T (p.R575X) Nonsense7,19,20 c.2178+1G>T Noncoding region20 3 Present c.1708G>A (p.A570T) Missense20 c.3634G>T (p.V1212F) Missense, predicted deleterious 4 Absent c.3164T>C (p.L1055P)* Missense, predicted deleterious 5 Absent c.3692G>A (p.R1231Q) Missense20 c.2296G>A (p.G766R) Missense20 6 Absent c.2782C>T (p.R928X) Nonsense13 c.3268C>T (p.R1090X) Nonsense5,7,13 7 Present c.3347G>A (p.G1116E) Missense, predicted deleterious IVS 23-8 G-A Noncoding region 8 Absent IVS 16-8 T>Gw Noncoding region10 9 Absent c.2944G>A (p.G982R) Missense5,7,19,20 c.2296G>A (p.G766R) Missense20 10 Absent c.2944G>A (p.G982R) Missense5,7,19,20 c.2296G>A (p.G766R) Missense20 11 Absent c.319T>C (p.C107R) Missense, predicted deleterious c.611+4A>G Noncoding region 12 Absent c.1723C>T (p.R575X) Nonsense7,19,20 c.2178+1G>T Noncoding region20 *Homozygous.
X
ABCB11 p.Gly982Arg 21490445:143:691
status: NEWX
ABCB11 p.Gly982Arg 21490445:143:770
status: NEW
PMID: 9806540
[PubMed]
Strautnieks SS et al: "A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis."
No.
Sentence
Comment
121
One Saudi Arabian family carries 2944 G→A (G982R), which is predicted to replace a glycine with an arginine, thereby disrupting transmembrane span 11.
X
ABCB11 p.Gly982Arg 9806540:121:50
status: NEW142 The ABC transporter family of proteins is the largest so far iden- Table 1• BSEP mutations found in PFIC patients Nucleotide mutation Amino acid number/ Protein consequence Families mutation 1723 C→T R575X Termination codon in first B2 heterozygous nucleotide binding fold Q homozygous 3169 C→T R1057X Termination codon in second B5 heterozygous nucleotide binding fold 908 del G 303 17 novel amino acids then truncation Family 57 heterozygous 3767-3768 ins C 1256 39 novel amino acids then truncation Family 99 homozygous 890 A→G E297G Glutamate to glycine in the intracellular loop S1, S3, S4B, S5, S6, S7, 38 homozygous between transmembrane spans 4 and 5 S4A, B5, B6, B7, 53, L heterozygous 1381 A→G K461E Lysine to glutamate in first Walker A motif Family 55 homozygous 1445 A→G D482G Aspartate to glycine in first P and 52 homozygous nucleotide binding fold 2944 G→A G982R Glycine to arginine in transmembrane span 11 Family 18 homozygous 3457 C→T R1153C Arginine to cysteine in second C and D homozygous nucleotide binding fold 3803 G→A R1268Q Arginine to glutamine in second J homozygous nucleotide binding fold In each case the nucleotide position in the human coding sequence is given along with details of the predicted protein consequence.
X
ABCB11 p.Gly982Arg 9806540:142:922
status: NEW236 The endonucleases used were: HphI (E297G), BpmI (K461E), FokI (D482G), AlwNI (G982R), BsrBI (R1153C) and AvaII (R1268Q).
X
ABCB11 p.Gly982Arg 9806540:236:78
status: NEW
PMID: 20103563
[PubMed]
Klaassen CD et al: "Xenobiotic, bile acid, and cholesterol transporters: function and regulation."
No.
Sentence
Comment
6508
Nucleotide Change Amino Acid Change In Vitro Function Protein Expression/ Localization ABCB11 BSEP N.D. G238V N.D. Intracellular A890G E297G 2 Intracellular N.D. C336S ↔ Normal G1296C R432T 2 Reduced T1331C V444A ↔ Normal/Reduced A1445G D482G 2 Normal/Reduced G2026T D676Y 2 Reduced G2563A G855R 2 Reduced G2944A G982R 2 Intracellular C3457T R1153C 2 Intracellular G3803A R1268Q 2 Intracellular searchers were able to identify functional roles for Mrp2 using rats lacking this transporter (Eisai hyperbilirubinemic rats on a Sprague-Dawley background and transport-deficient (TR-) on a Wistar background) (Paulusma et al., 1996; Ito et al., 1997).
X
ABCB11 p.Gly982Arg 20103563:6508:327
status: NEW
PMID: 16180115
[PubMed]
Ito K et al: "Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport."
No.
Sentence
Comment
240
Seven amino acid substitutions in BSEP, linked to PFICII (G238V, E297G, C336S, D482G, G982R, R1153C, R1268Q), have been reported and have been examined using rat Bsep expressed in MDCK (128).
X
ABCB11 p.Gly982Arg 16180115:240:86
status: NEW241 Five of these mutations resulted in disappearance from the apical surface in MDCK cells (G238V, E297G, G982R, R1153C, R1268R) (128).
X
ABCB11 p.Gly982Arg 16180115:241:103
status: NEW
PMID: 14699511
[PubMed]
Kullak-Ublick GA et al: "Enterohepatic bile salt transporters in normal physiology and liver disease."
No.
Sentence
Comment
117
It is caused by mutations of the BSEP (ABCB11) gene, which is located on chromosome 2q 24.173 Children with PFIC2 do not express BSEP.174 When PFIC2-related BSEP mutations are introduced artificially into rat Bsep and expressed in Madin-Darby canine kidney and Sf9 insect cells, the G238V, E297G, G982R, R1153C, and R1268Q mutations prevent the protein from trafficking to the apical membrane, whereas the G238V mutant seems to be rapidly degraded by proteasomes.175 Whereas mutation C336S affects neither Bsep transport activity nor trafficking, mutations E297G, G982R, R1153C, and R1268Q abolish taurocholate transport activity.
X
ABCB11 p.Gly982Arg 14699511:117:297
status: NEWX
ABCB11 p.Gly982Arg 14699511:117:564
status: NEW
PMID: 18395098
[PubMed]
Strautnieks SS et al: "Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families."
No.
Sentence
Comment
77
The common mutations E297G, D482G, R575X, R1153C, and R1153H abolish HphI, FokI, FokI, BsrBI, and BsrBI sites, respectively, while G982R creates an AlwNI site.
X
ABCB11 p.Gly982Arg 18395098:77:131
status: NEW150 Missense Mutations in ABCB11 Nucleotide change Predicted effect Exon CpG site Location Change in: Size Charge Hyd/Pol Shape c.149Tb0e;C p.Leu50Ser 4 No NH2 term Y Y Y c.470Ab0e;G p.Tyr157Cys 6 No TM2 Y Y Y c.725Cb0e;T p.Thr242Ile 8 No TM4 Y Y c.890Ab0e;G p.Glu297Gly 9 No IC2 Y Y Y c.908Gb0e;A p.Arg303Lys 9 No IC2 c.937Cb0e;A p.Arg313Ser 10 Yes IC2 Y Y Y Y c.980Gb0e;A p.Gly327Glu 10 No TM5 Y Y Y c.1168Gb0e;C p.Ala390Pro 11 No TM/NBF Y c.1229Gb0e;A p.Gly410Asp 12 No TM/NBF Y Y c.1238Tb0e;G p.Leu413Trp 12 No TM/NBF c.1388Cb0e;T p.Thr463Ile 13 No Adj Walker A Y Y Y c.1396Cb0e;A p.Gln466Lys 13 No Adj Walker A Y c.1409Gb0e;A p.Arg470Gln 13 Yes Adj Walker A Y c.1415Ab0e;G p.Tyr472Cys 13 No Adj Walker A Y Y Y c.1442Tb0e;A p.Val481Glu 14 No NBF1 Y Y Y c.1445Ab0e;G p.Asp482Gly 14 No NBF1 Y Y c.1460Gb0e;C p.Arg487Pro 14 Yes NBF1 Y Y Y Y c.1468Ab0e;G p.Asn490Asp 14 No NBF1 Y c.1535Tb0e;C p.Ile512Thr 14 No NBF1 Y Y Y c.1544Ab0e;C p.Asn515Thr 14 No NBF1 Y Y c.1550Gb0e;A p.Arg517His 14 Yes NBF1 Y Y c.1621Ab0e;C p.Ile541Leu 14 No NBF1 c.1622Tb0e;C p.Ile541Thr 14 No NBF1 Y Y Y c.1643Tb0e;A p.Phe548Tyr 15 No Adj ABC c.1685Gb0e;A p.Gly562Asp 15 No ABC Y Y c.1708Gb0e;A p.Ala570Thr 15 Yes ABC/Walker B Y c.1763Cb0e;T p.Ala588Val 15 No Adj Walker B Y c.2272Gb0e;C p.Gly758Arg 19 No NBF/TM Y Y Y c.2296Gb0e;A p.Gly766Arg 19 Yes TM7 Y Y Y c.2494Cb0e;T p.Arg832Cys 21 Yes IC3 Y Y Y Y c.2576Cb0e;G p.Thr859Arg 21 No IC3 Y Y Y Y c.2842Cb0e;T p.Arg948Cys 23 Yes IC4 Y Y Y Y c.2935Ab0e;G p.Asn979Asp 23 No TM11 Y c.2944Gb0e;A p.Gly982Arg 23 Yes TM11 Y Y Y c.3086Cb0e;A p.Thr1029Lys 24 No TM12 Y Y Y Y c.3329Cb0e;A p.Ala1110Glu 25 Yes Adj Walker A Y Y Y c.3382Cb0e;T p.Arg1128Cys 25 Yes Adj Walker A Y Y Y Y c.3457Cb0e;T p.Arg1153Cys 26 Yes NBF2 Y Y Y Y c.3458Gb0e;A p.Arg1153His 26 Yes NBF2 Y Y c.3460Tb0e;C p.Ser1154Pro 26 No NBF2 Y c.3628Ab0e;C p.Thr1210Pro 27 No Adj ABC Y c.3691Cb0e;T p.Arg1231Trp 27 Yes ABC/Walker B Y Y c.3692Gb0e;A p.Arg1231Gln 27 Yes ABC/Walker B Y c.3724Cb0e;A p.Leu1242Ile 27 No Walker B c.3892Gb0e;A p.Gly1298Arg 28 No NBF2 Y Y Y NOTE.
X
ABCB11 p.Gly982Arg 18395098:150:1620
status: NEW207 Ten mutations occurred in multiple families: R470Q, R832C,33 R948C, A1110E, and R1231Q53 have now been reported in 2 families; R1090X2 in 3 families; G982R,1,2 R1153C,1,47 and R1153H in 4 families; and R575X in 6 families.1,2,32,45 Six common missense and nonsense changes occurred at non-CpG sites: R520X and A588V33 in 2 European families and E1302X and I541L33,54 in 3 European families each.
X
ABCB11 p.Gly982Arg 18395098:207:150
status: NEW
PMID: 20800306
[PubMed]
Maggiore G et al: "Relapsing features of bile salt export pump deficiency after liver transplantation in two patients with progressive familial intrahepatic cholestasis type 2."
No.
Sentence
Comment
69
Patient Gender Patient 1 Female ABCB11 mutations Compound heterozygous c.301delCA p.Q101DfsX8 and c.2944G>A p.G982R with c.1331T>C p.V444A Negative 0.1 mmol/L 9 years SC P Growth failure Cirrhosis Hepatocellular cholestasis Giant hepatocytes Portal inflammation 36 234 N 17 Patient 2 Male Homozygous c.77-19T>A leading to abnormal splicing*: p.Y26Ifs7X Homozygous c.1331T>C p.V444A Negative NA 2.8 years SC P Growth failure Cirrhosis Hepatocellular cholestasis Giant hepatocytes 139 100 76 420 2xN 20 Canalicular BSEP staining Age at LT Indication Native liver histology PT (N >70%) Total bilirubin (N <17&#b5;mol/L) ALT (N <40 IU/L) AFP Serum liver tests at LT GGT (N <60 IU/L) Biliary bile acids (N >10 mmol/L) SC, severe cholestasis; P, pruritus refractory to medical management; PT, prothrombin time; ALT, alanine aminotransferase; AFP; alpha fetoprotein; GGT, gamma-glutamyl transpeptidase; BSEP, bile salt export pump, LT, liver transplantation; NA, not available; *, in silico test predicts abnormal splicing [2].
X
ABCB11 p.Gly982Arg 20800306:69:110
status: NEW
No.
Sentence
Comment
185
PFIC BRIC/NFC ICP Other liver diseases Genetic variants without disease association Missense mutations M1V C336S D549V L1055P E135K E137K T87R V43I S701P G19R W342G G556R C1083Y E137K L198P M123T S56L L712L L50S A382G G562D A1110E E186G E297G S194P Q121K A865D M62K R387H A570T S1114R L198P R415Q L198P R128H A865G C68Y A390P L581F G1116E E297G V444A G260D I206V S874P C107R G410D A588V G1116F G374S D482G E297K V284A I939M I112T L413W S593R G1116R A390P N591S V444A G295C R958Q W114R I420T I627T S1120N R432T T655I T510T G295R F959C Y157C D440E E636G R1128C V444A T655I G295S F959V A167T G455E R698C S1144R I498T D676Y R299K T965S A167V K461E S699P R1153C A570T P710P R303K F971L I182K T463I E709K R1153H T586I L827I L339V F971Y M183T Q466K G758R S1154P G648V G855R H423R L1006F M183V R470Q G766R N1173D T655I E1186K V444A N1009H G188W Y472C Y818F T1210P T923P V444D K1145N M217R V481E R832C N1211D A926P V444G I1183T R223C D482G R832H V1212F R948C A459V S226L R487H T859R R1231Q G1004D I468I G238V R487P A865V R1231W R1050C R487L T242I N490D Q869P L1242I G1116R Q546K A257G I498T G877R D1243G R1128H Q558H V284L G499E S901R R1268Q L1197G E592Q E297G I512T R948C A1283V R1231Q V597M R303G N515T N979D G1292V R616G R303K R517H G982R G1298R T619A Q312H F540L G1004D M677L R313S I541L T1029K M677V G327E I541T G1032R R696Q W330R F548Y A1044P R698H Nonsense mutations (premature stop-codons) S25X Y472X Y772X R1090X E96X W493X Q791X V1147X W330X R520X R928X Q1215X Y354X I528X Y1041X R1235X R415X R575X R1057X E1302X R470X Q702X Q1058X Table 1 (Continued) PFIC BRIC/NFC ICP Other liver diseases Genetic variants without disease association Splice site mutations 76 + 3G > T 908 + 1delG 2178 + 1G > T 3057-2A > G Q159Q 77-1G > C 908 + 1G > T 2179-2A > G 3213 + 1delG Q361Q 99-1G > T 908 + 1G > A 2343 + 1G > T 3213 + 4A > G 150 + 3A > C 1435-13 -8del 2343 + 2T > C 3213 + 5G > A 390-1G > A 2012-8T > G 2611-2A > T 611 + 1G > A 2178 + 1G > A R1001R Deletions/insertions/frame shifts Q101Dfs8X L380Wfs18X G648Vfs5X Q1058Hfs38X F959Hfs1X T127Hfs6X A382 A388del K700Sfs12X I1061Vfs34X F959Gfs48X N199Ifs14X P456Pfs24X T919del L1165del L232Cfs9X H484Rfs5X K930Efs92X A1192Efs50X R303Sfs17X I528Sfs21X K930Efs79X T1256Tfs40X V368Rfs27X I610Qfs45X K969 K972del Synonymous variants without disease association R33R F90F L232L I416I G557G I876I A1028A K1145K D36D I134I Y269Y G418G V597V G937G K1070K R52R S136S Q312Q F427F A804A Y981Y T1086T D58D V195V G319G E395E A535A G817G G1004G A1110A The overview shows ࣈ 290 known variants of BSEP on the protein level, except splice site mutations, which are shown on cDNA level.
X
ABCB11 p.Gly982Arg 22795478:185:1227
status: NEW
PMID: 23685087
[PubMed]
Soroka CJ et al: "Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations."
No.
Sentence
Comment
136
When seven PFIC2 missense mutations were expressed in MDCK cells, five of these common mutations (G238V, E297G, G982R, R1153C and R1268Q) were unable to traffic to the apical membrane (Wang et al., 2002).
X
ABCB11 p.Gly982Arg 23685087:136:112
status: NEW185 In vitro studies using rat Bsep mutants of the human mutations G238V, D482G, G982R, R1153C, and R1268Q all resulted in retention of Bsep in the ER to different extents (Wang et al., 2008).
X
ABCB11 p.Gly982Arg 23685087:185:77
status: NEW207 A preliminary report from the same group finds that 4-PBA decreases pruritus and serum bile acid concentrations, and improves liver function within 3 months of treatment in 3 PFIC2 children harboring a least one missense mutation (A257V, G982R and T1210P) (Gonzales et al., 2012b).
X
ABCB11 p.Gly982Arg 23685087:207:238
status: NEW
PMID: 23722250
[PubMed]
Kagawa T et al: "Ursodeoxycholic acid stabilizes the bile salt export pump in the apical membrane in MDCK II cells."
No.
Sentence
Comment
11
UDCA significantly increased the activity of Bsep with a benign recurrent intrahepatic cholestasis 2 mutation (A570T) but did not affect Bsep with a progressive familial intrahepatic cholestasis 2 mutation (G982R or D482G).
X
ABCB11 p.Gly982Arg 23722250:11:207
status: NEW88 MDCK-Ntcp cells were transfected with an expression vector that contained mutated Bsep, including any of a PFIC2 mutation (G982R or D482G) and a BRIC2 mutation (A570T) [11].
X
ABCB11 p.Gly982Arg 23722250:88:123
status: NEW90 Basal Bsep activity was slightly lower in the A570T mutant (80.6 % of the wild-type Bsep activity) and much lower in the G982R (15.3 %) and D482G (18.8 %) mutants compared with that in wild-type Bsep (Fig. 6).
X
ABCB11 p.Gly982Arg 23722250:90:121
status: NEW93 In contrast, UDCA did not affect the activity of the G982R and D482G mutant proteins.
X
ABCB11 p.Gly982Arg 23722250:93:53
status: NEW163 The inability of TUDCA to stimulate Bsep activity was unexpected because this molecule has been reported to 0 50 100 150 200 wild-type A570T G982R D482G UDCA - + - + - + - + * ** Bsep activity (%) Fig. 6 The effect of UDCA on mutant Bsep activity.
X
ABCB11 p.Gly982Arg 23722250:163:141
status: NEW164 MDCK II cells stably expressing wild-type or mutant (A570T, G982R, or D482G) Bsep were incubated in the presence or absence of UDCA (100 lM) for 24 h after preincubation with sodium butyrate (5 mM) for 24 h. Thereafter, these cells were incubated for 1 h at 37 &#b0;C with [3 H]-TC (1 lM) and cold TC (10 lM) in the lower compartment. The intracellular accumulation and transcellular flux of TC were calculated on the basis of the radioactivity in the total cells and apical medium, respectively. Bsep activity was determined by the permeability-surface area product for TC transport across the apical membrane (PSapical), which was calculated as (rate of transcellular TC flux)/(intracellular TC concentration).
X
ABCB11 p.Gly982Arg 23722250:164:60
status: NEW175 Negligible Bsep activity was observed for the G982R and D482G mutants, which cause PFIC2.
X
ABCB11 p.Gly982Arg 23722250:175:46
status: NEW
No.
Sentence
Comment
112
The missense mutations p.G238V, p.E297G, p.G982R, p.R1153C and p.R1268Q all led to a reduced expression at the apical membrane, when expressed in MDCK cells [124].
X
ABCB11 p.Gly982Arg 25027376:112:43
status: NEW113 It was shown in vitro that the two BSEP mutations p.Y818F and p.G982R caused intracellular retention of BSEP.
X
ABCB11 p.Gly982Arg 25027376:113:64
status: NEW137 BSEP/Bsep NTCP ASBT Exon skipping E186G G1116R G319G R1128C T463I R1128H A926P E1186K A1028Aa R1231W A1110E Aberrant splicing E297K R1153H R832C S1154P S1144R No splice product T586I R1231Q Reduced plasma membrane expression E135K A570T I223T E297Gb N591Sb V444A R1050C Intracellular retention Y818F G982R Reduced or absent bile salt transport A570T R432T A64T K314E V98Ic M264V I206V Q558H I223T C144Y P290S E297Gb N591Sb S267F L243P G374S E1186K I279T T262M a A1028A induces significant exon skipping in vitro but probably not in vivo (unpublished data; Dro &#a8;ge, Ha &#a8;ussinger, Kubitz).
X
ABCB11 p.Gly982Arg 25027376:137:300
status: NEW
PMID: 25085279
[PubMed]
Davit-Spraul A et al: "Liver transcript analysis reveals aberrant splicing due to silent and intronic variations in the ABCB11 gene."
No.
Sentence
Comment
42
Patient 2 is compound heterozygous for the missense mutation p.Gly982Arg and the silent substitution of unknown significance c.3003ANG (p.Arg1001Arg) in exon 23.
X
ABCB11 p.Gly982Arg 25085279:42:63
status: NEW44 Patient 4 is compound heterozygous for the non-sense mutation p.Tyr354X and the missense mutation p.Gly982Arg.
X
ABCB11 p.Gly982Arg 25085279:44:100
status: NEW71 Maternal allele Paternal allele Patient 1 c.3213+4ANG p.Val444Ala&#b0; p.Arg1153Cys p.Val444Ala&#b0; Patient 2 p.Gly982Arg p.Val444Ala&#b0; p.Phe90Phe&#b0; c.3003ANG (silent p.Arg1001) Patient 3 p.Gly1003Glu p.Val444Ala&#b0; p.Ala1028Ala** p.Tyr1041X p.Val444Ala&#b0; Patient 4 p.Tyr354X p.Gly319Gly* p.Met677Val&#b0; p.Ala1028Ala** c.389+8GNA p.Gly982Arg Patient 5 p.Arg1128Cys* p.Val444Ala&#b0; p.Met677Val&#b0; p.Thr1086Thr p.Arg1128Cys p.Val444Ala&#b0; p.Met677Val&#b0; p.Thr1086Thr In bold: disease-causing mutation. In italic: common variation.
X
ABCB11 p.Gly982Arg 25085279:71:113
status: NEWX
ABCB11 p.Gly982Arg 25085279:71:346
status: NEW
PMID: 25342496
[PubMed]
Kubitz R et al: "Autoimmune BSEP disease: disease recurrence after liver transplantation for progressive familial intrahepatic cholestasis."
No.
Sentence
Comment
51
The three mutations/variants Y818F, G982R, and V444A have been found on the same allele in a PFIC-2 patient.
X
ABCB11 p.Gly982Arg 25342496:51:36
status: NEW52 BSEP with Y818F together with G982R is poorly expressed.
X
ABCB11 p.Gly982Arg 25342496:52:30
status: NEW87 Sex Age at LTX (years) Zygosity Nucleotide change Predicted (protein) effect BSEP expression (before LTX) BSEP autoantibodies detected Symptom recurrence- time after LTX (years) Triggering factors 1 [22, 63] F 3.5/3.5/4.9 hom hom c.2453A>T c.2944G>A p.Y818F p.G982R Absent (exp) Yes 1/0.4 Graft rejection after first LTX 2 [23] M 5.2 hom c.907A>G p.R303G Absent Yes 12 Unknown 3 [23] F 3.7 com het c.1741C>T IVS12+1G>T a p.L581F abb splic Absent Yes 3.5/5.2/8.1/12.1/13 EBV infection; corticosteroids 4 [23] F 2.2 hom IVS17+1T>A a abb splic Absent Yes 2.1/4 Low CsA, switch from Tac to CsA 5 [62, 63] F 9 com het c.301delCA c.2944G>A p.Q101Dfs8X p.G982R Absent NA 3.3/17 IS, pregnancy?
X
ABCB11 p.Gly982Arg 25342496:87:260
status: NEWX
ABCB11 p.Gly982Arg 25342496:87:656
status: NEW112 Following this report, similar observations were published (1) K930Efs79X wtBSEP (2) (3) (4) R1050C (7) D482G G374S (6) (5) c.150+3A>C (8) G982R Fig. 2 Different effects of genetic ABCB11 variants on processing and function of BSEP.
X
ABCB11 p.Gly982Arg 25342496:112:139
status: NEW
No.
Sentence
Comment
71
ABCB11 mutations and immunostaining in patients with ABCB11 mutations Patient ID Sex Nucleotide change Amino acid change Mutation origin BSEP expression GGT expression 244 Female c.145C>T/- p.Q49X/- Paternal/- Absent Normal 653 Female c.1197+1G>T/c.1197+1G>T -/- Paternal/maternal Not assessed Not assessed 727 Male c.2782C>T/c.3593A>G p.R928X/p.H1198R Maternal/paternal Not assessed Not assessed 889 Female c.3457C>T/c.3623A>G p.R1153C/p.Y1208C Paternal/maternal Absent Normal 919 Female c.1493T>C/c.1493T>C p.I498T/p.I498T Paternal/maternal Not assessed Not assessed 996 Male c.612-2_4 CTA>TT/- -/- Maternal/- Absent Normal 1022 Male c.212T>A/c.677C>T p.L71H/p.S226L Paternal/maternal Absent Normal 1131 Male c.409G>A/c.2216delC p.E137K/p.P740QfsX6 De novo/paternal Absent Normal 1134 Male c.1760C>G/c.3677G>C p.S587X/p.R1226P Maternal/paternal Absent Absent 1139 Female c.2935A>G/c.3746T>G p.N979D/p.L1249X Not assessed Not assessed Not assessed 1140 Male c.542G>T/c.1370_1372dupGTG p.R181I/p.V458dup Maternal/paternal Not assessed Not assessed 1219 Female c.872T>C/c.3691C>T p.V291A/p.R1231W Maternal/paternal Not assessed Not assessed 334* Female c.2944G>A/- p.G982R/- Not assessed Normal Normal 802* Female c.3458G>A/- p.R1153H/- Not assessed Not assessed Not assessed 862* Male c.634G>A/c.849A>C/c.1638G>T p.A212T/p.E283D/p.Q546H Maternal/maternal/de novo Not assessed Not assessed 864* Male c.1727A>G/- p.N576S/- Paternal/- Normal Normal 1165* Male c.1583T>C/c.1583T>C p.I528T/p.I528T Not assessed Not assessed Not assessed 1167* Male c.334A>G/c.3233T>C p.I112V/p.I1078T Not assessed Not assessed Not assessed 1242* Male c.2783G>A/- p.R928Q/- Not assessed Not assessed Not assessed Bold: Novel mutation.
X
ABCB11 p.Gly982Arg 26382629:71:1166
status: NEW